<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052776</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01057</org_study_id>
    <nct_id>NCT04052776</nct_id>
  </id_info>
  <brief_title>Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES</brief_title>
  <acronym>STIMO-PHARMA</acronym>
  <official_title>Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With Spinal Cord Injury Treated With Epidural Electrical Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ecole Polytechnique Fédérale de Lausanne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a current first-in-man study, called Stimulation Movement Overground (STIMO) (NCT02936453;&#xD;
      CER-VD: 04-2014; Swissmedic: 2016-MD-0002), epidural electrical stimulation (EES) of the&#xD;
      spinal cord is applied to enable individuals with severe spinal cord injury (SCI) to complete&#xD;
      intensive locomotor neurorehabilitation training. In this clinical feasibility study, it was&#xD;
      demonstrated that EES results in an immediate enhancement of locomotor functions and that&#xD;
      when applied repeatedly as part of a neurorehabilitation program, EES can progressively&#xD;
      improve leg motor control in individuals with severe SCI. Mechanistically, EES acts&#xD;
      trans-synaptically upon spinal circuitries through the electrical stimulation of&#xD;
      proprioceptive fibers.&#xD;
&#xD;
      It is assumed that this stimulation does not increase the level of availability of monoamine&#xD;
      neurotransmitters below the SCI level, which are essential for lower extremity movement&#xD;
      generation. Specifically, in a non-injured individual, dopamine and serotonin synthesized in&#xD;
      the brain and brainstem are released by fibers diffusely innervating the spinal cord, serving&#xD;
      to critically mediate excitability of motor neurons and interneurons in lumbar and sacral&#xD;
      spinal level. Spinal cord injury would partially or entirely disrupt these modulation&#xD;
      pathways, resulting in a detrimental lack of crucial neurotransmitters below the injury&#xD;
      level. This lack of endogenous neurotransmitters could potentially be compensated for by&#xD;
      pharmacological agents promoting the neurochemical environment necessary for locomotion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim is to test the effects of orally administered buspirone and levodopa/carbidopa taken&#xD;
      individually and in combination. Both buspirone and levodopa can cross the blood-brain&#xD;
      barrier, and reach the lumbar spinal cord where 5-HT1A receptors are expressed, and levodopa&#xD;
      can presumably be synthesized by specialized dopaminergic into dopamine. Alternatively,&#xD;
      levodopa effects might be mediated via noradrenaline, following dopamine metabolization.&#xD;
      Therefore, it is hypothesized that the combination of pharmacological neuromodulation with&#xD;
      EES would further improve locomotor functions and lower extremity motor score.&#xD;
&#xD;
      The primary and safety objective is to evaluate the safety and the tolerability of a&#xD;
      single-dose of immediate-release levodopa/carbidopa, buspirone, the combination&#xD;
      levodopa/carbidopa and buspirone, and the placebo in individuals with SCI.&#xD;
&#xD;
      The secondary objectives are to assess the following effects of levodopa/carbidopa,&#xD;
      buspirone, the combination levodopa/carbidopa and buspirone, and the placebo on the lower&#xD;
      extremities:&#xD;
&#xD;
        1. Spasticity&#xD;
&#xD;
        2. Lower Extremity Motor score (LEMS)&#xD;
&#xD;
        3. Voluntary movements&#xD;
&#xD;
        4. Gait patterns and velocity Participants' safety will be ensured with the usage of Rysen,&#xD;
           which a CE-marked bodyweight support system robot, and the aid of locomotor assistive&#xD;
           device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Anticipated">May 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 4, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study will be monocentric, randomized, double-blind, placebo-controlled with a four-sequence crossover design.&#xD;
All participants will undergo the 4 treatment arms. and each of them will be their own control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded and undistinguishable pills will be made by a pharmacy laboratory in order to conceal their nature from the clinicians and the participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of AEs/SAEs/Side effects</measure>
    <time_frame>Changes from baseline condition over a treatment session of 4 hours</time_frame>
    <description>Evaluate the safety of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo.&#xD;
The frequency and the severity AEs and SAEs will be collected thoughout the treatment session&#xD;
Reported side effects throughout the treatment sessions will also be collected by a tailored quantitative/qualitative questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in blood pressure</measure>
    <time_frame>Changes from baseline condition over a treatment session of 4 hours</time_frame>
    <description>Evaluate the safety of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo&#xD;
-Vitals signs will be monitored throughout the treatment session to evaluate the fluctuations from baseline condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in heart rate</measure>
    <time_frame>Changes from baseline condition over a treatment session of 4 hours</time_frame>
    <description>Evaluate the safety of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo&#xD;
-Vitals signs will be monitored throughout the treatment session to evaluate the fluctuations from baseline condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spasticity of the Lower Extremities (score according to the Pendulum test)</measure>
    <time_frame>Changes from baseline condition over a treatment session of 4 hours</time_frame>
    <description>Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo.&#xD;
-Assessment of the lower extremities' spasticity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower Extremity Motor Strength (M0-M5 score according to the AIS)</measure>
    <time_frame>Changes from baseline condition over a treatment session of 4 hours</time_frame>
    <description>Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo.&#xD;
-Assessment of the lower extremities' motor strength by a clinician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower Extremity Motor Strength (muscle activity)</measure>
    <time_frame>Changes from baseline condition over a treatment session of 4 hours</time_frame>
    <description>Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo.&#xD;
-Assessment of the lower extremities' motor strength by EMGs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower Extremity Voluntary Movements (kinematics assessment through VICON)</measure>
    <time_frame>Changes from baseline condition over a treatment session of 4 hours</time_frame>
    <description>Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo.&#xD;
-Participants' voluntary movements will be assessed by kinematics analyses through the VICON)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower Extremity Voluntary Movements (muscle activity)</measure>
    <time_frame>Changes from baseline condition over a treatment session of 4 hours</time_frame>
    <description>Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo.&#xD;
-Participants' muscles during the voluntary movements will be assessed by EMGs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking speed (10MWT)</measure>
    <time_frame>Changes from baseline condition over a treatment session of 4 hours</time_frame>
    <description>Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo.&#xD;
-Participants' velocity will be assessed with a 10MWT with and without EES</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait pattern (kinematics assessment through VICON)</measure>
    <time_frame>Changes from baseline condition over a treatment session of 4 hours</time_frame>
    <description>Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo.&#xD;
-Participants' gait pattern during a 10MWT will be assessed by kinematics analyses through the VICON</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait pattern (muscle activity)</measure>
    <time_frame>Changes from baseline condition over a treatment session of 4 hours</time_frame>
    <description>Explore preliminary efficacy of oral, single-dose administration of levodopa/carbidopa, buspirone, the combination of buspirone and levodopa/carbidopa, and placebo.&#xD;
-Participants' muscle activity will be assessed during a 10MWT with EMGs.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <condition>Drug Effect</condition>
  <arm_group>
    <arm_group_label>Buspirone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa-Carbidopa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400mg/100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buspirone + Levodopa-Carbidopa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40mg + 400mg/100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Mannitol pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone</intervention_name>
    <description>40mg</description>
    <arm_group_label>Buspirone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa-Carbidopa</intervention_name>
    <description>400mg/100mg</description>
    <arm_group_label>Levodopa-Carbidopa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone + Levodopa-Carbidopa</intervention_name>
    <description>40mg + 400mg/100mg</description>
    <arm_group_label>Buspirone + Levodopa-Carbidopa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Non-active metabolite</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Completed the main phase of the STIMO study&#xD;
&#xD;
          -  Enrolled in the STIMO study extension&#xD;
&#xD;
          -  Age 18-65 (women or men)&#xD;
&#xD;
          -  Sensorimotor or motor complete and incomplete SCI graded as AIS A, B, C &amp; D&#xD;
&#xD;
          -  Stable medical, physical and psychological condition as considered by Investigators&#xD;
&#xD;
          -  Able to understand and interact with the study team in French or English&#xD;
&#xD;
          -  Adequate caregiver support and access to appropriate medical care in the patient's&#xD;
             home community&#xD;
&#xD;
          -  Agree to comply with all conditions of the study and to attend all required study&#xD;
             training and visit&#xD;
&#xD;
          -  Must provide and sign Informed Consent prior to any study-related procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Women who are pregnant (pregnancy test obligatory for women of childbearing potential)&#xD;
             or breastfeeding or not willing to take contraception.&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol abuse.&#xD;
&#xD;
          -  Gastrointestinal ulcers in the last five years&#xD;
&#xD;
          -  Known or suspected eye disorders or diseases&#xD;
&#xD;
          -  Known or suspected allergies or hypersensitivity to buspirone, levodopa or carbidopa.&#xD;
&#xD;
          -  Taking selective and non-selective serotonin reuptake inhibitors or any other&#xD;
             treatments acting upon serotonergic transmission, such as the following:&#xD;
&#xD;
               -  Selective serotonin reuptake inhibitors (SSRIs)&#xD;
&#xD;
               -  Serotonin-norepinephrine reuptake inhibitors (SNRIs)&#xD;
&#xD;
               -  Serotonin antagonists and reuptake inhibitors (SARIs)&#xD;
&#xD;
               -  Tricyclic antidepressants (TCAs)&#xD;
&#xD;
               -  Tetracyclic antidepressants (TeCAs)&#xD;
&#xD;
               -  Norepinephrine-dopamine reuptake inhibitors (NDRIs)&#xD;
&#xD;
               -  Monoamine oxidase inhibitors (MAOIs)&#xD;
&#xD;
          -  Patients who are receiving treatments altering the noradrenergic and dopaminergic&#xD;
             transmission (e.g., bupropion and levodopa/carbidopa)&#xD;
&#xD;
          -  Patients who are taking narcotic pain killers (e.g., opioids) and neuropathic&#xD;
             medication (e.g., gabapentin, pregabalin)&#xD;
&#xD;
          -  Patients who are taking antihypertensive drugs and diuretics (e.g., furosemide or&#xD;
             hydrochlorothiazide)&#xD;
&#xD;
          -  Patients who are taking hypnotic drugs (e.g., Zolpidem).&#xD;
&#xD;
          -  Patients receiving D2 antagonists or antipsychotic drugs (e.g., butyrophenone,&#xD;
             phenothiazines, risperidone)&#xD;
&#xD;
          -  Other clinically significant concomitant disease states (e.g., renal failure, hepatic&#xD;
             dysfunction, cardiovascular disease, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jocelyne Bloch, Pr MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://courtine-lab.epfl.ch/</url>
    <description>Courtine-Lab is a part of the Center for Neuroprosthetic and Brain Mind Institute of the Life Science School at the Swiss Federal Institute of Technology Lausanne (EPFL). The laboratory is headed by Professor Courtine</description>
  </link>
  <link>
    <url>https://www.chuv.ch/fr/chuv-home/</url>
    <description>The clinical trial is located at the CHUV in Lausanne, Switzerland.</description>
  </link>
  <reference>
    <citation>Wagner FB, Mignardot JB, Le Goff-Mignardot CG, Demesmaeker R, Komi S, Capogrosso M, Rowald A, Seáñez I, Caban M, Pirondini E, Vat M, McCracken LA, Heimgartner R, Fodor I, Watrin A, Seguin P, Paoles E, Van Den Keybus K, Eberle G, Schurch B, Pralong E, Becce F, Prior J, Buse N, Buschman R, Neufeld E, Kuster N, Carda S, von Zitzewitz J, Delattre V, Denison T, Lambert H, Minassian K, Bloch J, Courtine G. Targeted neurotechnology restores walking in humans with spinal cord injury. Nature. 2018 Nov;563(7729):65-71. doi: 10.1038/s41586-018-0649-2. Epub 2018 Oct 31.</citation>
    <PMID>30382197</PMID>
  </reference>
  <reference>
    <citation>Formento E, Minassian K, Wagner F, Mignardot JB, Le Goff-Mignardot CG, Rowald A, Bloch J, Micera S, Capogrosso M, Courtine G. Electrical spinal cord stimulation must preserve proprioception to enable locomotion in humans with spinal cord injury. Nat Neurosci. 2018 Dec;21(12):1728-1741. doi: 10.1038/s41593-018-0262-6. Epub 2018 Oct 31.</citation>
    <PMID>30382196</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Jocelyne Bloch</investigator_full_name>
    <investigator_title>Professor Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Pharmacology</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>Epidural electrical stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The SAP, CSR, AEs, SAEs will be made available to other researchers once the study is completed and data have been analyzed</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Three years after</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

